Furthermore, the third-generation EGFR-TKI, Osimertinib, has been shown to elevate the ROS levels in NSCLC cells, leading to mitochondrial impairment and cellular apoptosis [19]. Here, EGFR is linked to non-small cell lung carcinoma.